Form 4: Centessa Pharmaceuticals Executive Karen M. Anderson Reports Share Sales and Option Exercises

Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, reported the exercise of share options and subsequent sale of ordinary shares on March 25, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 25, 2024, Karen M. Anderson, Chief People Officer of Centessa Pharmaceuticals, exercised share options to acquire 25,010 shares at $4.01 and 19,990 shares at $3.85.
• Following the option exercises, Anderson sold 29,995 shares at a weighted average price of $11.6561 (ranging from $11.07 to $12.035) and 21,165 shares at a weighted average price of $12.2058 (ranging from $12.07 to $12.40).
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 23, 2023.
• After these transactions, Anderson directly owns 71,525 ordinary shares and holds options for 335,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The existence of a 10b5-1 plan suggests the sales were pre-planned and not necessarily indicative of the officer's current outlook on the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge management's sentiment and confidence in the company's prospects.

Stakeholder Impact

• Shareholders may interpret the insider selling activity in various ways, potentially affecting investor sentiment.

Key Dates